Nektar Therapeutics (NKTR +15% premarket) will receive up to $1.12B from AstraZeneca (AZN) for...

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

Nektar Therapeutics (NKTR +15% premarket) will receive up to $1.12B from AstraZeneca (AZN) for its NKTR-118 and NKTR-119 constipation drugs, including $125M upfront to license NKTR-118, another $235M if it achieves certain milestones, and $375M more if it hits commercial success milestones.